Has anyone had any luck trying to quantify Nextera XT libraries using qPCR? I have tried it twice with no success. I have been able to quantify TruSeq libraries and they have been working just right. It looks like primer sequences are correct, so I don't know what could be causing the problem.
-
-
Yes, we got a library, already normalized and eluted as single strands using the kit protocol. The protocol called for us to just heat denature it, snap cool and immediately load into the reagent cassette for sequencing. But we did a KAPA qPCR kit (not the Illumina-specific kit, just the generic one) using normal flow cell oligo primers. The result looked fairly reasonable, so we proceeded. Basically just did what the protocol asked. (Okay, I spiked in phiX out of paranoia -- but otherwise the followed the instructions on the box.)
Worked okay.
--
Phillip -
You've had luck with the bead normalization? I've never been able to get it to work. Anytime I use the beads I get a uneven distribution of up to 50%. That's why I'm relying on qPCR to quantify my library.Comment
-
You get better than 0.5x variation in read numbers using qPCR? Like you have several samples in a pool and the lowest one gave you 20 million and the highest gave you 30 million? That would be close enough to perfect to satisfy me!
I did not do the bead normalization myself -- we just got a Nextera XT pool from a customer and ran it. There were >20 different index pairs in it. I generally call it a "win" if the lowest sample gives > 1/2 the number of reads as the highest sample. So by that criteria, it was good. Actually, if I remember correctly, it was better than that.
--
PhillipComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...Today, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment